Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinomaYang Zhang, Rui‐Hua Xu, Gao-Zhun Xiong et al.|Cell Reports Medicine|2022Cited by 51